Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02216838 · ClinicalTrials.gov registry record · Phase 4
Treatment of Facial Flushing With Botulinum Toxin A Injections
A Phase 4 study of Facial Flushing, sponsored by Northwestern University.
- Active
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02216838: Active Phase 4 study of Facial Flushing, sponsored by Northwestern University.
NCT02216838 is a Phase 4 study of Facial Flushing that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 16 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02216838, a Phase 4 study of Facial Flushing, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if botulinum toxin A (botox®) can be used to treat facial flushing. This study is a pilot study designed to determine feasibility of these procedures.
Primary Outcome
Spectrophotometer measurement as the percent resolution on each follow up visit compared to baseline visit
Conditions Studied
Interventions
- DRUG botulinum toxin A
- OTHER Saline Control
Study Locations (1)
Illinois
- Northwestern University Feinberg School of Medicine, Department of Dermatology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-08 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What the registry record for NCT02216838 still lists
NCT02216838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Facial Flushing appearing as the primary indexed condition, and to 2 interventions - of which botulinum toxin A is the first listed.
NCT02216838 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02216838 about?
NCT02216838 is a clinical study titled "Treatment of Facial Flushing With Botulinum Toxin A Injections". The purpose of this study is to find out if botulinum toxin A (botox®) can be used to treat facial flushing. This study is a pilot study designed to determine feasibility of these procedures.
What is the current status of trial NCT02216838?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2014-08. Estimated completion is 2025-12.
What conditions does trial NCT02216838 study?
This clinical trial studies the following conditions: Facial Flushing.
What interventions are being tested in trial NCT02216838?
The interventions under investigation include: botulinum toxin A (DRUG), Saline Control (OTHER).
Who is sponsoring clinical trial NCT02216838?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02216838 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02216838's enrollment target sits among peer trials
16 1870th of 2000 higher than 121 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia